OncoCyte (NYSEAMERICAN:OCX) released its earnings results on Tuesday. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01, Fidelity Earnings reports.
Shares of OCX stock traded up $0.15 during mid-day trading on Wednesday, reaching $4.43. The company’s stock had a trading volume of 511 shares, compared to its average volume of 946,544. OncoCyte has a 1-year low of $1.16 and a 1-year high of $6.92.
A number of equities analysts have recently issued reports on the stock. Janney Montgomery Scott upgraded shares of OncoCyte from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 29th. Piper Jaffray Companies assumed coverage on shares of OncoCyte in a research note on Wednesday, February 13th. They issued an “overweight” rating and a $6.00 price objective for the company. Zacks Investment Research upgraded shares of OncoCyte from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Thursday, January 17th. Lake Street Capital increased their price objective on shares of OncoCyte from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, January 29th. Finally, Chardan Capital restated a “buy” rating and issued a $7.75 price objective on shares of OncoCyte in a research note on Thursday, April 25th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.95.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
See Also: Different Options Trading Strategies
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.